Posted by Michael Wonder on 18 Oct 2022
Axoft brain implant technology is granted FDA breakthrough device designation
18 October 2022 - Axoft today launched and announced FDA breakthrough device designation for its brain-machine interface to better treat neurological disorders.
The company secured $8 million in capital to fund pre-clinical studies with the FDA and to scale up prototypes of its neural implants “as soft as the brain.”
